ReviewCurrent opinion in virology2025
Status of advanced respiratory syncytial virus antiviral therapeutics 2025.
Review in Current opinion in virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of nebulized inhalation vs. intramuscular delivery of interferon α1b injection for paediatric patients with viral respiratory diseases: a systematic review and meta-analysis.Frontiers in pediatrics · 2025Pooled it
- Twenty-five years of human metapneumovirus research.Clinical microbiology reviews · 2026Review
- SMAD4-BPIFA1 Axis Governs Airway Antiviral Defense in Myhre Syndrome.Biomolecules · 2026Article
- Computational Identification of Potential RSV L-RdRp Inhibitors with Predicted Superior Activity and Safety Profiles over Remdesivir Using QSAR Modeling, Molecular Docking and Molecular Dynamics Simulations.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Epidemiology and subtype analysis of respiratory syncytial virus among hospitalized children under five in Isfahan during early 2024.Iranian journal of microbiology · 2026Article
- Structural Advances in Respiratory Syncytial Virus: Implications for Vaccine and Antiviral Development.Microorganisms · 2026Review
- Challenges and opportunities in the management of severe pneumonia. Key concepts from the Seventh Annual Meeting of Spanish Experts 2025.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Review
- Global trends and advances in pediatric bronchiolitis treatment in the last two decades: a bibliometric analysis.Journal of thoracic disease · 2026Article
- Article
- An LNP antiviral siRNA drug cocktail delivered intranasally is effective against a range of respiratory viruses.Virology journal · 2026Article
- The soluble G protein of respiratory syncytial virus promotes viral dissemination via TLR2-mediated NLRP3 priming and pyroptosis.Npj viruses · 2026Article
- Insights Into monoclonal antibodies and vaccines targeting respiratory viruses.Frontiers in pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Respiratory syncytial virus (RSV) causes major morbidity and mortality in vulnerable populations. In infants, RSV infection is a leading cause of hospitalization and can result to severe respiratory complications marked by bronchiolitis and viral pneumonia. Currently, prophylaxis exists in the form of three licensed vaccines, all approved for adults aged >65 years or pregnant women, but no vaccination is available specifically for infants. Prophylactic monoclonal antibody treatments, palivizumab and nirsevimab, are recommended in some instances for newborns, but treatment cost and need for intravenous administration limit universal accessibility. The only antiviral approved for the RSV indication, ribavirin, is no longer recommended for clinical use, creating an urgent need for a novel generation of effective therapeutics. Extensive anti-RSV drug discovery efforts have long been dominated by viral entry inhibitors that emerged as pharmacodominant in automated drug discovery campaigns, yet more recently developed candidates have expanded the target range to the viral polymerase complex and nucleoprotein. Focusing on advanced therapeutic candidates and investigational drugs that have entered clinical trials, this review will discuss challenges in RSV drug development in perspective of recent breakthroughs in RSV prophylaxis, assess the current stage of RSV therapeutic candidates, and identify key requirements for future improved RSV disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.